Comprehensive Lung Panel
| Label Mnemonic: | LUNG DX PAN |
| Epic code: | LAB8580 |
| Downtime form: | Doctor/Provider Orders - Pathology Molecular |
Molecular Pathology
6240 RCP
384-9568
6240 RCP
384-9568
Specimen(s):
Formalin Fixed, Paraffin Embedded Tissue Block or 10 unstained 4-8 micron thick sections on non-plus slides and an H&E slide of the tissue
Minimum:
Specimen requires 20% or greater tumor cell content.
Testing Schedule:
Weekly
Turn Around
Time:
2 weeks
Test
Limitations:
Testing is not currently validated for microsatellite instability (MSI) or mutation load analyses. Please contact the laboratory director for questions. Testing is not validated for use on plasma for cell-free tumor DNA mutation testing.
Methodology:
Massively parallel Next Generation DNA sequencing by synthesis, Illumina technology
CPT Code:
81445, 81455, 88342, 88341
Testing is performed from paraffin-embedded tissue of the tumor.
Substitutions and small insertion/deletions are detected in these genes: ABL1, ACVR1, AKT1, AKT2, AKT3, ALK, ANKRD26, APC, AR, ARAF, ARID1A, ATM, ATR, ATRX, AURKA, AXL, BAP1, BARD1, BIRC3, BLM, BRAF, BRCA1, BRCA2, BRIP1, BTK, CBL, CCND1, CCND2, CCND3, CCNE1, CD28, CDH1, CDK12, CDK2, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTNNB1, DAXX, DDR2, DDX3X, DHX15, DICER, DNMT3A, DOT1L, EED, EGFR, EPHA3, ERBB2, ERBB3, ERBB4, ERCC2, ERRFI1, ESR1, ETNK1, ETV6, EZH2, FAM175A, FANCA, FANCC, FANCD2, FANCI, FANCL, FBXW7, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FOXL2, FUBP1, GATA1, GATA2, GATA3, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HIST1H3C, HNF1A, HRAS, IDH1, IDH2, IGF1R, IGF2, JAK1, JAK2, JAK3, KDR, KIT, KLR4, KMT2D, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAPK3, MAX, MCL1, MDM2, MDM4, MED12, MET, MLH1, MPL, MRE11A, MSH2, MSH6, MTOR, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NOTCH1, NOTCH2, NOTCH3, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1, POLE, PPARG, PPP2R1A, PTCH1, PTEN, PTPN11, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAF1, RB1, RET, RHEB, RHOA, RICTOR, RNF43, ROS1, SDHA, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SF3B1, SIRT2, SLIT2, SLX4, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, SMO, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STK11, SUFU, TERT, TET2, TOP1, TP53, TRAF7, TSC1, TSC2, TYK2, U2AF1, U2AF2, WT1, XPO1, and ZBTB7A.
Copy number alterations (gains or losses) are detected in these genes: AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN2A, CDKN2B, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, PTEN, RICTOR, SOX2, TERT, TSC1, and TSC2.
Fusion transcripts are detected and reported involving rearrangements of these genes: AKT1, ALK, AXL, CCND1, EGFR, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, and ROS1.